Floatz logo

Therapeutic Asset Ratings

204 results matching 1 filter

129,767 assets · 8,707 sponsors · 3,128 indications
Methodology v0.2
AssetSponsorPhaseRating
Tbi-1301
Lung Cancer
University Health Network, TorontoP1C (37)
Tcr-T Cells
Lung Cancer
Beijing DCTY Biotech Co.,Ltd.P1C (37)
Tilt-123
Lung Cancer
TILT Biotherapeutics Ltd.P1C (37)
Vsv-02
Lung Cancer
The First Affiliated Hospital of Xinxiang Medical CollegeP1C (37)
Wm-A1-3389
Lung Cancer
Wellmarker BioP1C (37)
Zn-C3
Lung Cancer
M.D. Anderson Cancer CenterP1C (37)
ic9.gd2.car.il-15 t-cells
Lung Cancer
UNC Lineberger Comprehensive Cancer CenterEarly P1C (34)
R130
Lung Cancer
Shanghai Yunying Medical TechnologyEarly P1C (34)
Recombinant L-Ifn Adenovirus
Lung Cancer
Shanghai Fengxian District Central HospitalEarly P1C (34)
Luveltamab Tazevibulin
Lung Cancer
Sutro Biopharma, Inc.P2D (29)
[18f]f-resca-epcd6
Lung Cancer
RenJi HospitalN/AD (28)
18F-WL12
Lung Cancer
Peking University Cancer Hospital & InstituteN/AD (28)
[68ga]ga-nota-epcd6
Lung Cancer
RenJi HospitalN/AD (28)
68ga-my
Lung Cancer
Peking University Cancer Hospital & InstituteN/AD (28)
68Ga-WL12
Lung Cancer
Peking University Cancer Hospital & InstituteN/AD (28)
Acetylsalicylic Acid
Lung Cancer
Hospital Universitari Vall d'Hebron Research InstituteN/AD (28)
BLOOD, WHOLE
Lung Cancer
UNC Lineberger Comprehensive Cancer CenterN/AD (28)
compound solution of sodium chloride
Lung Cancer
Cukurova UniversityN/AD (28)
Copper Cu 64 Anti-Cea Monoclonal Antibody M5A
Lung Cancer
City of Hope Medical CenterN/AD (28)
DEXKETOPROFEN
Lung Cancer
Brigham and Women's HospitalN/AD (28)
Dupilumab
Lung Cancer
Shanghai University of Traditional Chinese MedicineN/AD (28)
METAMIZOLE
Lung Cancer
Brigham and Women's HospitalN/AD (28)
METARAMINOL
Lung Cancer
Hospital Universitari Vall d'Hebron Research InstituteN/AD (28)
Midodrine
Lung Cancer
Hospital Universitari Vall d'Hebron Research InstituteN/AD (28)
NEPENTHE
Lung Cancer
Brigham and Women's HospitalN/AD (28)
Showing 176 to 200 of 204 assets
PreviousPage 8 of 9Next